Roche’s House Advantage: Does Having It All Under One Roof Make A Difference?

The size of Roche’s pipeline and in-house diagnostics business are key advantages in oncology, top execs told the firm’s analyst meeting at ASCO. Roche’s oncology strategy includes replicating its HER2 success in hematology, targeting new pathways, entering immunotherapy and going all-in on antibody-drug conjugates.